## Hideki Koizumi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6993887/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical Factors Related to Loculation of Fluid in Central Serous Chorioretinopathy. American Journal of Ophthalmology, 2022, 235, 197-203.	3.3	15
2	Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 1857-1865.	1.9	17
3	Scleral Thickness in Steroid-Induced Central Serous Chorioretinopathy. Ophthalmology Science, 2022, 2, 100124.	2.5	10
4	Dry age-related macular degeneration in the Japanese population. Japanese Journal of Ophthalmology, 2022, 66, 8-13.	1.9	2
5	CILIOCHOROIDAL EFFUSION IN CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2022, 42, 730-737.	1.7	13
6	Imbalanced choroidal circulation in eyes with asymmetric dilated vortex vein. Japanese Journal of Ophthalmology, 2022, 66, 14-18.	1.9	8
7	Short-term results for brolucizumab in treatment-naÃ⁻ve neovascular age-related macular degeneration: a Japanese multicenter study. Japanese Journal of Ophthalmology, 2022, 66, 379-385.	1.9	9
8	Reply to "Comment on Clinical Factors Related to Loculation of Fluid in Central Serous Chorioretinopathy― American Journal of Ophthalmology, 2022, 241, 295.	3.3	1
9	Scleral Thickness in Central Serous Chorioretinopathy. Ophthalmology Retina, 2021, 5, 285-291.	2.4	71
10	Retrospective exploratory analyses on gender differences in determinants for incidence and progression of diabetic retinopathy in Japanese patients with type 2 diabetes mellitus. Endocrine Journal, 2021, 68, 655-669.	1.6	8
11	Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 2857-2859.	1.9	35
12	Temporary changes of visual outcomes and anterior chamber parameters after phacoemulsification and low-add-power segmented intraocular lens implantation for primary angle closure disease. International Ophthalmology, 2021, 41, 2485-2494.	1.4	0
13	Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan. Scientific Reports, 2021, 11, 13152.	3.3	12
14	Rapid formation of macular pucker following intravitreal ranibizumab injection for branch retinal vein occlusion. American Journal of Ophthalmology Case Reports, 2021, 23, 101192.	0.7	0
15	Short Axial Length Is Related to Asymmetric Vortex Veins in Central Serous Chorioretinopathy. Ophthalmology Science, 2021, 1, 100071.	2.5	10
16	Short axial length and hyperopic refractive error are risk factors of central serous chorioretinopathy. British Journal of Ophthalmology, 2020, 104, bjophthalmol-2019-315236.	3.9	15
17	Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration. Ophthalmology Retina, 2020, 4, 767-776.	2.4	30
18	Macular atrophy after aflibercept therapy for neovascular age-related macular degeneration: outcomes of Japanese multicenter study. Japanese Journal of Ophthalmology, 2020, 64, 338-345.	1.9	9

Нідекі Коізимі

#	Article	IF	CITATIONS
19	Latest Developments in Polypoidal Choroidal Vasculopathy: Epidemiology, Etiology, Diagnosis, and Treatment. Asia-Pacific Journal of Ophthalmology, 2020, 9, 260-268.	2.5	21
20	Pachychoroid disease. Eye, 2019, 33, 14-33.	2.1	443
21	Differences in Choroidal Structures Between Idiopathic and Steroid-Induced Central Serous Chorioretinopathy. Journal of Vitreoretinal Diseases, 2019, 3, 10-15.	0.7	4
22	Anterior chamber paracentesis during intravitreal injections in observational trials: effectiveness and safety and effects. International Journal of Retina and Vitreous, 2019, 5, 8.	1.9	21
23	Association of Upregulated Angiogenic Cytokines With Choroidal Abnormalities in Chronic Central Serous Chorioretinopathy. , 2018, 59, 5924.		32
24	Comparison of subfoveal choroidal structures in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Japanese Journal of Ophthalmology, 2018, 62, 576-583.	1.9	10
25	Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy. Japanese Journal of Ophthalmology, 2018, 62, 584-591.	1.9	16
26	Distinct Aqueous Humour Cytokine Profiles of Patients with Pachychoroid Neovasculopathy and Neovascular Age-related Macular Degeneration. Scientific Reports, 2018, 8, 10520.	3.3	67
27	Structural analyses of choroid after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy. British Journal of Ophthalmology, 2017, 101, 433-437.	3.9	58
28	Polypoidal Choroidal Vasculopathy. Retina, 2016, 36, 1-8.	1.7	160
29	Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2016, 123, 617-624.	5.2	106
30	Reply. American Journal of Ophthalmology, 2016, 168, 287-288.	3.3	0
31	Short-Term Changes in Choroidal Thickness After Aflibercept Therapy for Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2015, 159, 627-633.e1.	3.3	91
32	Reply. American Journal of Ophthalmology, 2015, 160, 207-208.	3.3	0
33	Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study. British Journal of Ophthalmology, 2015, 99, 1284-1288.	3.9	36
34	One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy. Ophthalmology, 2015, 122, 1866-1872.	5.2	114
35	SUBFOVEAL CHOROIDAL THICKNESS IN RETINAL ANGIOMATOUS PROLIFERATION. Retina, 2014, 34, 1316-1322.	1.7	55
36	Changes in fundus autofluorescence after treatments for polypoidal choroidal vasculopathy. British Journal of Ophthalmology, 2014, 98, 780-784.	3.9	15

Нідекі Коізимі

#	Article	IF	CITATIONS
37	Relationship Between Clinical Characteristics of Polypoidal Choroidal Vasculopathy and Choroidal Vascular Hyperpermeability. American Journal of Ophthalmology, 2013, 155, 305-313.e1.	3.3	148
38	Subfoveal Choroidal Thickness after Ranibizumab Therapy for Neovascular Age-related Macular Degeneration: 12-Month Results. Ophthalmology, 2012, 119, 1621-1627.	5.2	152
39	Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2011, 249, 1123-1128.	1.9	283
40	Predictive factors of resolved retinal fluid after intravitreal ranibizumab for polypoidal choroidal vasculopathy. British Journal of Ophthalmology, 2011, 95, 1555-1559.	3.9	35
41	Blue light and near-infrared fundus autofluorescence in acute Vogt-Koyanagi-Harada disease. British Journal of Ophthalmology, 2010, 94, 1499-1505.	3.9	39
42	Enhanced Depth Imaging Spectral-Domain Optical Coherence Tomography. American Journal of Ophthalmology, 2008, 146, 496-500.	3.3	1,914
43	INDOCYANINE GREEN ANGIOGRAPHY IN EYES WITH SUBSTANTIALLY INCREASED SUBRETINAL FLUID 1 WEEK AFTER PHOTODYNAMIC THERAPY. Retinal Cases and Brief Reports, 2008, 2, 12-14.	0.6	4